Mar 6 |
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
|
Mar 5 |
Trim the Fat: 3 Overbought Stocks Poised for a Pullback
|
Mar 5 |
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
Mar 4 |
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
|
Feb 28 |
Elevation Oncology to Participate in Upcoming Investor Conferences
|
Feb 23 |
3 Stock Winners That Are Up 400% or More in 2024
|
Feb 22 |
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
|
Jan 31 |
How Is The Market Feeling About Elevation Oncology?
|
Jan 22 |
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
|
Jan 17 |
Elevation Oncology: Rising On News, But Not The Time To Buy
|